Pharma News

Keep updating your pharma knowledge
1 Apr 2016

Blockbuster “Sofosbuvir” Hepatitis C drug now under price control in India

National Pharmaceutical Pricing Authority (NPPA) has brought under price control revolutionary drug ‘Sofosbuvir’ prescribed for patients with Hepatitis C.

Sofosbuvir cannot be sold for more than Rs619.31 per tablet starting April 1, according to a gazette notification dated March 29. The drug currently has an MRP of Rs19,800-Rs25,000 for 28 tablets (Rs705-Rs900 for a tablet), depending on the brand name it is sold under.

Combination drug Sofosbuvir + Ledipasavir, popularly known by the brand name ‘Harvoni’, is generally used by those with Hep C genotypes 1, 4, 5 and 6. This combination is not under price control.

In recent time, many Indian pharmaceutical companies launched Sofosbuvir with licensing from Gliead.

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!